Organon & Co (OGN)

Organon & Co. is a healthcare company whose common stock is listed on the NYSE under the ticker OGN. The company focuses on women’s health and markets prescription therapies and medical devices across the United States, Europe, Canada, Japan, the rest of Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and other international markets. Its women’s health portfolio includes contraceptive and fertility products such as Nexplanon, NuvaRing, Cerazette, Marvelon, Mercilon, Follistim AQ, Elonva, Ganirelix acetate injection, Jada, and Xaciato. Organon also sells biosimilars across immunology and oncology, along with medicines for cholesterol management, hypertension, respiratory conditions, seasonal allergies, dermatology, bone health, non-opioid pain management, benign prostatic hyperplasia, and male pattern hair loss. The company serves wholesalers, retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Founded in 1923, Organon is headquartered in Jersey City, New Jersey.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.